Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gemini Space Station Inc (GEMI) vs Illumina, Inc. (ILMN) Price & Performance

Gemini Space Station IncTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Gemini Space Station Inc vs Illumina, Inc. — how do they compare? Gemini Space Station Inc trades at $4.36 (market cap $582.14M), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 69.5× Gemini Space Station Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Illumina, Inc. for 83 Days on average.

GEMIILMN
Market Cap
$582.14M$40.43B
Volume
1,995,8022,948,626
Sector
FinancialsHealth
52-Week High
$25.41$293.69
52-Week Low
$3.54$91.00
Typical Hold Time
14 Days83 Days
Enterprise Value
$561.16M$41.79B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gemini Space Station Inc

Gemini Space Station (GEMI) trades at $4.49, down 3.85% today, with a bearish technical signal despite oversold RSI readings. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$517 million. Recent news highlights expansion into commission-free stock trading and prediction markets, though the stock faces class action lawsuits alleging securities violations.

The outlook remains challenged by persistent losses and negative cash flow from operations, offset by financing activities. Analyst consensus is mixed with a $5.33 price target (48% upside), but high business execution and regulatory risks warrant caution. The stock's valuation appears stretched given profitability concerns, making it speculative for risk-tolerant investors.

Illumina, Inc.

Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.

The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GEMI
30% Buy70% Sell
Avg holding period · 14 Days
ILMN
96% Buy4% Sell
Avg holding period · 83 Days

Top news

Latest headlines on both assets

About Gemini Space Station Inc

Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.

Read more on GEMI →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →